Researchers have designed acid-sensitive bionic nanocarriers based on ApoE peptide-modified erythrocyte membranes for the delivery of Bcl-2/Bcl-xl and Mcl-1 inhibitors to treat glioblastoma (GBM). The gene discussed is MCL1; the disease is glioblastoma.